MM120 (LSD D-Tartrate) Clinical Trials (2026): 5 Studies for Generalized Anxiety Disorder & ADHD

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

5 MM120 (LSD D-Tartrate) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Generalized Anxiety Disorder & ADHD) and 859 total planned enrollment. 3 Phase 3 MM120 (LSD D-Tartrate) trials and 2 Phase 2 are listed. Most recent activity: NCT06941844 (May 2027).

MM120 (LSD D-Tartrate) clinical trials at a glance: phase × recruitment status

Phaseactive not recruitingcompletedTotal
P222
P333

MM120 (LSD D-Tartrate) clinical trials by indication

Generalized Anxiety Disorder (2)

NCTAcronymPhaseStatusTitle
NCT06809595P3active not recruitingA Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06741228P3active not recruitingA Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Major Depressive Disorder (1)

NCTAcronymPhaseStatusTitle
NCT06941844P3active not recruitingA Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

Anxiety Generalized (1)

NCTAcronymPhaseStatusTitle
NCT05407064P2completedA Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

ADHD (1)

NCTAcronymPhaseStatusTitle
NCT05200936P2completedSafety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

All MM120 (LSD D-Tartrate) trials (5)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06941844A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)P3active not recruiting149Definium Therapeutics US, Inc.Apr 2025
NCT06809595A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)P3active not recruiting245Definium Therapeutics US, Inc.Jan 2025
NCT06741228A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)P3active not recruiting214Definium Therapeutics US, Inc.Dec 2024
NCT05200936Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept TrialP2completed53Definium Therapeutics US, Inc.Dec 2021
NCT05407064A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsP2completed198Definium Therapeutics US, Inc.Aug 2022

MM120 (LSD D-Tartrate) clinical trials: frequently asked questions

How many MM120 (LSD D-Tartrate) clinical trials are there?
5 MM120 (LSD D-Tartrate) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are marked completed.
Are MM120 (LSD D-Tartrate) clinical trials recruiting in 2026?
No active MM120 (LSD D-Tartrate) trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
What conditions is MM120 (LSD D-Tartrate) being studied for?
MM120 (LSD D-Tartrate) is being studied for Generalized Anxiety Disorder, ADHD, Anxiety Generalized, Attention Deficit Disorder, Major Depressive Disorder. The trials are grouped by indication on this page.
What phase is MM120 (LSD D-Tartrate) in?
MM120 (LSD D-Tartrate) clinical trials span 3 Phase 3, 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors MM120 (LSD D-Tartrate) clinical trials?
The lead sponsor across the most MM120 (LSD D-Tartrate) trials is Definium Therapeutics US, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MM120 (LSD D-Tartrate)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: